RxDoctor Payments Data

Jeffrey Montgomery, DO

Family Medicine · Clarks Summit, PANPI 1902007990

Payments from drug & device makers

$40,219in general payments, 2019–2025

Across 1,529 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$16K
  • AbbVie$7K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • plus $8K from 45 others

What the payments were for

  • Consulting fees$5,11313%
  • Speaking & faculty fees$14,61336%
  • Food & beverage$20,34851%
  • Education$1460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,219 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,945
Medicare patients
256
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$158,314
EliquisApixaban126$99,825
JardianceEmpagliflozin37$33,170
XareltoRivaroxaban51$32,971
JanuviaSitagliptin Phosphate31$28,229
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$27,246
MounjaroTirzepatide24$25,335
RybelsusSemaglutide17$22,457
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$14,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,567
TradjentaLinagliptin18$12,651
Tresiba Flextouch U-200Insulin Degludec11$11,621
GlyxambiEmpagliflozin/Linagliptin12$10,438
MyrbetriqMirabegron21$9,501
BrilintaTicagrelor12$5,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,846$180,771148 claims
PfizerEliquis, Paxlovid$1,648$102,683140 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$1,488$56,25967 claims
Johnson & JohnsonXarelto$473$32,97151 claims
MerckJanuvia$655$28,22931 claims
Lilly USA, LLCMounjaro$1,548$25,33524 claims
GSKTrelegy Ellipta$440$13,56723 claims
Astellas Pharma US IncMyrbetriq$107$9,50121 claims
AstraZenecaBrilinta$2,009$5,39712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Clarks Summit

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →